Insight

Patrizia Giannatempo: Phase 1/2 Duravelo-1 study

Patrizia Giannatempo/X

May 28, 2025, 03:50

Patrizia Giannatempo: Phase 1/2 Duravelo-1 study

Patrizia Giannatempo, Medical Oncology Consultant at the National Cancer Institute (INT) in Milan, shared a post on X:

“ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2).
Bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). Encouraging tolerability.”

Title: Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

Authors: Patrizia Giannatempo, Matthew Galsky, Ignacio Duran, Valentina Boni, Andrea Necchi, Antoine Italiano, Meredith McKean, Loic Verlingue, Rama Balaraman, Leslie DeMars, Kate Josephs, Cong Xu, Oscar Reig Torras

Read the Full Article.

Patrizia Giannatempo

Andrea Necchi Antoine Italiano ASCO25 cancer Cancer research Cong Xu Ignacio Duran Kate Josephs Leslie DeMars Loic Verlingue Matthew Galsky Meredith McKean OncoDaily Oncology Oscar Reig Torras Patrizia Giannatempo Rama Balaraman Valentina Boni

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action